B
Belite Bio, Inc (BLTE)
NCM – Real Time Price. Currency in USD
155.54
+3.57 (2.35%)
At close: May 12, 2026, 4:00 PM EDT
156.50
+0.96 (0.62%)
After-hours: May 12, 2026, 4:18 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
155.54
+3.57 (2.35%)
At close: May 12, 2026, 4:00 PM EDT
156.50
+0.96 (0.62%)
After-hours: May 12, 2026, 4:18 PM EDT
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
There is no data to display
| Date | Type | Document |
|---|---|---|
| 2026-04-21 | 6-K | tm2611999d1_6k.htm |
| 2026-03-31 | 6-K | tm261133d2_6k.htm |
| 2026-03-02 | 6-K | tm267429d1_6k.htm |
| 2026-01-30 | S-8 | tm264429d1_s8.htm |
| 2026-01-27 | 6-K | tm264022d1_6k.htm |
| 2025-11-10 | 6-K | tm2530713d1_6k.htm |
| 2025-10-22 | F-3ASR | tm2529080-1_f3asr.htm |
| 2025-09-08 | 6-K | tm2525484d1_6k.htm |
| 2025-08-11 | 6-K | tm2522879d1_6k.htm |
| 2025-08-07 | 6-K | tm2522848d1_6k.htm |